セルベースアッセイ市場 – 2030年までの世界予測

この調査レポートでは、セルベースアッセイ（細胞ベースアッセイ）市場を{消耗品[試薬、アッセイキット（レポーター遺伝子アッセイ、細胞増殖アッセイ、二次メッセンジャーアッセイ、細胞死アッセイ、その他のアッセイキット）、マイクロプレート、細胞株（不死化細胞株、初代細胞株、幹細胞株）、プローブとラベル、その他の消耗品]、機器、ソフトウェア、サービス}、技術（フローサイトメトリー、ハイスループットスクリーニング、ラベルフリー検出、その他の技術）、用途[創薬（毒物学、薬力学、薬物動態学）、基礎研究、遺伝子研究、その他の用途]、エンドユーザー（製薬およびバイオ製薬会社、受託研究機関（CRO）、学術研究機関）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。本レポートは、細胞ベースアッセイ市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。業界の主要プレーヤーを包括的に分析し、各社の事業概要、製品、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。また、新製品の発売、提携、買収、そして細胞ベースアッセイ市場に関連する最近の動向に関する情報も含まれています。

Report Overview

The cell-based assays market is projected to reach USD 27.55 billion by 2030 from an estimated USD 17.84 billion in 2025, at a CAGR of 9.1% during the forecast period from 2025 to 2030. This growth can be largely attributed to the increasing demand for drug discovery and the rising need for cell-based assays in this area. Furthermore, higher research & development investments from the pharmaceutical and biotechnology industries are driving the growth of the cell-based assays market. Additionally, the growing incidence of cancer is increasing the demand for advanced therapies, which further boosts market expansion. The expanding applications of cell-based assays in chronic diseases and personalized medicine are also expected to propel market growth in the coming years.

セルベースアッセイ市場は、2025年の推定178億4,000万米ドルから2030年には275億5,000万米ドルに達すると予測されており、2025年から2030年の予測期間中、年平均成長率（CAGR）9.1%で成長します。この成長は、主に創薬需要の増加と、この分野における細胞ベースアッセイの需要の高まりに起因しています。さらに、製薬業界およびバイオテクノロジー業界による研究開発投資の増加も、細胞ベースアッセイ市場の成長を牽引しています。さらに、がんの発生率増加に伴い、先進的な治療法への需要が高まっており、市場拡大をさらに後押ししています。慢性疾患や個別化医療における細胞ベースアッセイの用途拡大も、今後数年間の市場成長を牽引すると予想されます。

“The drug discovery segment accounted for the largest share of the application segment in 2024.”

The cell-based assays market is segmented by application into drug discovery, basic research, genetic studies, and other applications. The drug discovery segment is further categorized into toxicity, pharmacokinetic, and pharmacodynamic studies. In 2024, the drug discovery segment accounted for the largest share of the global cell-based assays market. The increasing prevalence of cancer is driving the demand for advanced therapies, which, in turn, promotes the growth of this segment within the cell-based assays market. Additionally, rising investments in research and development, the introduction of new drugs, and a growing number of contract research organizations offering drug discovery services to pharmaceutical and biotechnology companies are also expected to contribute to the segment’s continued growth in the cell-based assays market.

“The flow cytometry segment accounted for a major share of the technology market in 2024.”

The cell-based assays market is categorized by technology into flow cytometry, high-throughput screening, label-free detection, and other technologies. In 2024, flow cytometry held the largest share of the global cell-based assays market within this category. The growth of the flow cytometry segment is primarily due to its widespread use in cell-based assays, allowing for multiple measurements. Additionally, the increasing adoption of advanced technologies for cell analysis and characterization is expected to further enhance the growth of this segment in the cell-based assays market.

“The US dominated the cell-based assays market in 2024.”

The cell-based assays market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, the US dominated the cell-based assays market in North America. As the largest biopharmaceutical market in the world, the US leads in biopharmaceutical research and investments. The country also boasts a robust healthcare infrastructure that supports research and development in the life sciences sector.

Additionally, the significant presence of numerous biopharmaceutical companies and increased research activities in the biotechnology industry are driving market growth in the US. Furthermore, the rising emphasis on developing advanced cell-based therapies, prompted by the increasing incidence of cancer, contributes to the growth of the cell-based assays market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (60%) and Demand Side (40%)
• By Designation: Managers (45%), CXOs & Directors (30%0, and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report:

• BD (US)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Lonza (Switzerland)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• REVVITY (US)
• Sartorius AG (Germany)
• Corning Incorporated (US)
• Promega Corporation (US)
• Cell Signaling Technology, Inc. (US)
• Eurofins Scientific (Luxembourg)
• Enzo Biochem, Inc. (US)
• Carna Biosciences, Inc. (Japan)
• Intertek Group Plc (UK)
• BICO (Sweden)
• Cell Biolabs, Inc. (US)
• Reaction Biology (US)
• AAT Bioquest, Inc. (US)
• Pestka Biomedical Laboratories, Inc. (US)
• Neuromics (US)
• BPS Bioscience, Inc. (US)
• BellBrook Labs (US)
• Profacgen (US)
• BMG LABTECH (Germany)
• Hanugen Therapeutics (India)
• Altogen Labs (US)
• BioAgilytix (US)

Research Coverage:

This research report categorizes the cell-based assays market by offering {consumables [reagents, assay kits (reporter gene assays, cell growth assays, secondary messenger assays, cell death assays, and other assay kits), microplates, cell lines (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables], instruments, software, and services}, technology (flow cytometry, high-throughput screening, label-free detection, and other technologies), application [drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications], end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This analysis also includes information about new product launches, collaborations, acquisitions, and recent developments related to the cell-based assays market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, a surge in cases of cancer, and increasing R&D investments and funding for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market.
• Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), REVVITY (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group Plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), Altogen Labs (US), and BioAgilytix (US).

Table of Contents

1               INTRODUCTION              38

1.1           STUDY OBJECTIVES       38

1.2           MARKET DEFINITION   38

1.3           STUDY SCOPE   39

1.3.1        INCLUSIONS & EXCLUSIONS       39

1.3.2        MARKET SEGMENTATION AND REGIONAL SCOPE                 40

1.3.3        YEARS CONSIDERED      41

1.3.4        CURRENCY CONSIDERED            41

1.4           STAKEHOLDERS               41

1.5           SUMMARY OF CHANGES               42

2               RESEARCH METHODOLOGY       43

2.1           RESEARCH DATA              43

2.1.1        SECONDARY DATA          44

2.1.2        PRIMARY DATA 45

2.2           MARKET SIZE ESTIMATION         46

2.2.1        GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH)       46

2.2.2        INSIGHTS FROM PRIMARY EXPERTS        48

2.2.3        SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)       49

2.3           MARKET GROWTH RATE PROJECTIONS                50

2.4           DATA TRIANGULATION                52

2.5           RESEARCH ASSUMPTIONS           52

2.6           RISK ANALYSIS  53

2.7           RESEARCH LIMITATIONS             54

3               EXECUTIVE SUMMARY  55

4               PREMIUM INSIGHTS       59

4.1           ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CELL-BASED ASSAYS MARKET                59

4.2           NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2024)              60

4.3           CELL-BASED ASSAYS MARKET, BY OFFERING, 2024                 60

4.4           CELL-BASED ASSAYS MARKET, BY END USER, 2024                 61

4.5           CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              61

5               MARKET OVERVIEW       62

5.1           INTRODUCTION              62

5.2           MARKET DYNAMICS       62

5.2.1        DRIVERS               64

5.2.1.1    Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery       64

5.2.1.2    Government support and funding for cell-based research                 65

5.2.1.3    Growing efforts to curtail animal-based studies              66

5.2.1.4    Rising prevalence of cancer 66

5.2.1.5    Alliances to accelerate innovations in drug discovery     68

5.2.2        RESTRAINTS      69

5.2.2.1    High cost of instruments and restrictions imposed by product

end-user licenses for reagents             69

5.2.2.2    Lack of standardization of protocols used in cell-based assays                 69

5.2.3        OPPORTUNITIES              70

5.2.3.1    Growing applications of cell-based assays in chronic diseases and personalized medicine         70

5.2.3.2    Growth opportunities in emerging economies 71

5.2.3.3    Rising adoption of AI in drug discovery and cell analysis                 72

5.2.4        CHALLENGES    73

5.2.4.1    Complexities in assay designs             73

5.2.4.2    Shortage of skilled professionals        73

5.3           TECHNOLOGY ANALYSIS             73

5.3.1        KEY TECHNOLOGIES     73

5.3.1.1    Flow cytometry     73

5.3.1.2    High-throughput screening                 74

5.3.1.3    High-content screening       74

5.3.1.4    Label-free detection             75

5.3.2        COMPLEMENTARY TECHNOLOGIES       75

5.3.2.1    Artificial intelligence and machine learning     75

5.3.3        ADJACENT TECHNOLOGIES       76

5.3.3.1    Nanotechnology    76

5.4           VALUE CHAIN ANALYSIS               76

5.5           PRICING ANALYSIS          78

5.5.1        AVERAGE SELLING PRICE TREND OF KEY PLAYERS,

BY PRODUCT, 2021–2024                79

5.5.2        AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024     80

5.6           ECOSYSTEM ANALYSIS  80

5.6.1        RAW MATERIAL VENDORS           81

5.6.2        PRODUCT/SERVICE VENDORS  81

5.6.3        END USERS         82

5.6.4        REGULATORY BODIES  82

5.7           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            83

5.8           PATENT ANALYSIS          83

5.8.1        NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE,

2014–2025              84

5.9           KEY CONFERENCES & EVENTS, 2025–2026              86

5.10         TARIFF AND REGULATORY LANDSCAPE               86

5.10.1      TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS                 86

5.10.2      REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  87

5.10.3      REGULATORY FRAMEWORK       90

5.10.3.1  North America      90

5.10.3.2  Europe   90

5.10.3.3  Asia Pacific            90

5.10.3.4  Rest of the World 91

5.11         PORTER’S FIVE FORCES ANALYSIS           92

5.11.1      THREAT OF NEW ENTRANTS      93

5.11.2      THREAT OF SUBSTITUTES          93

5.11.3      BARGAINING POWER OF SUPPLIERS       93

5.11.4      BARGAINING POWER OF BUYERS             93

5.11.5      INTENSITY OF COMPETITIVE RIVALRY 93

5.12         KEY STAKEHOLDERS & BUYING CRITERIA            94

5.12.1      KEY STAKEHOLDERS IN BUYING PROCESS           94

5.12.2      BUYING CRITERIA           95

5.13         INVESTMENT AND FUNDING SCENARIO               96

5.14         TRADE ANALYSIS             97

5.14.1      IMPORT DATA  97

5.14.2      EXPORT DATA  99

5.15         IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET               100

5.16         IMPACT OF 2025 US TARIFF ON CELL-BASED ASSAYS MARKET               102

5.16.1      INTRODUCTION              102

5.16.2      KEY TARIFF RATES          102

5.16.3      PRICE IMPACT ANALYSIS             103

5.16.4      IMPACT ON COUNTRY/REGION                104

5.16.4.1  US           104

5.16.4.2  Europe   104

5.16.4.3  Asia Pacific            104

5.16.5      IMPACT ON END-USE INDUSTRIES          105

5.16.5.1  Pharmaceutical & biotech companies                105

5.16.5.2  Contract research organizations (CROs)         106

5.16.5.3  Academic & research institutes          106

6               CELL-BASED ASSAYS MARKET, BY OFFERING     107

6.1           INTRODUCTION              108

6.2           CONSUMABLES 108

6.2.1        REAGENTS          113

6.2.1.1    High demand for reagents in research applications to

propel market growth           113

6.2.2        ASSAY KITS         116

6.2.2.1    Reporter gene assays            120

6.2.2.1.1 Versatility of reporter gene assays and widespread applications to fuel growth             120

6.2.2.2    Cell growth assays                 124

6.2.2.2.1 Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market                124

6.2.2.3    Secondary messenger assays               128

6.2.2.3.1 Adoption of secondary messenger assays for cell signaling studies to fuel growth        128

6.2.2.4    Cell death assays  132

6.2.2.4.1 Importance of cell death quantification in drug development to favor growth          132

6.2.2.5    Other assay kits    135

6.2.3        MICROPLATES  138

6.2.3.1    Demand for microplates in assay development to drive market                 138

6.2.4        CELL LINES         141

6.2.4.1    Immortalized cell lines         144

6.2.4.1.1 Wide use of immortalized cell lines to boost market       144

6.2.4.2    Primary cell lines  147

6.2.4.2.1 Advantages in drug development, preclinical research, and other applications to propel market             147

6.2.4.3    Stem cell lines       151

6.2.4.3.1 Rising use in tissue and disease models to fuel adoption                 151

6.2.5        PROBES & LABELS            154

6.2.5.1    Growing need for effective cell labeling to boost demand                 154

6.2.6        OTHER CONSUMABLES 158

6.3           INSTRUMENTS 161

6.3.1        AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH  161

6.4           SERVICES             165

6.4.1        GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH             165

6.5           SOFTWARE         168

6.5.1        INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS

TO DRIVE GROWTH        168

7               CELL-BASED ASSAYS MARKET, BY TECHNOLOGY                 171

7.1           INTRODUCTION              172

7.2           FLOW CYTOMETRY         172

7.2.1        WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO

DRIVE MARKET 172

7.3           HIGH-THROUGHPUT SCREENING           176

7.3.1        INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH    176

7.4           LABEL-FREE DETECTION             179

7.4.1        GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND        179

7.5           OTHER TECHNOLOGIES               183

8               CELL-BASED ASSAYS MARKET, BY APPLICATION                 186

8.1           INTRODUCTION              187

8.2           DRUG DISCOVERY           187

8.2.1        TOXICITY STUDIES         191

8.2.1.1    Increasing demand for cell-based assays in toxicity testing to

fuel growth             191

8.2.2        PHARMACOKINETIC STUDIES   195

8.2.2.1    Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays              195

8.2.3        PHARMACODYNAMIC STUDIES 199

8.2.3.1    Advantages of cell-based assays in pharmacodynamics to

propel growth        199

8.3           BASIC RESEARCH              203

8.3.1        INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES  203

8.4           GENETIC STUDIES          207

8.4.1        INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET 207

8.5           OTHER APPLICATIONS 210

9               CELL-BASED ASSAYS MARKET, BY END USER      214

9.1           INTRODUCTION              215

9.2           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 215

9.2.1        GROWTH IN R&D EFFORTS TOWARD CELL-BASED ASSAYS IN PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTORS TO DRIVE MARKET     215

9.3           CONTRACT RESEARCH ORGANIZATIONS             220

9.3.1        GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR

CELL-BASED ASSAYS IN CONTRACT RESEARCH 220

9.4           ACADEMIC & RESEARCH INSTITUTES    224

9.4.1        RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS

TO DRIVE MARKET         224

10            CELL-BASED ASSAYS MARKET, BY REGION          228

10.1         INTRODUCTION              229

10.2         NORTH AMERICA             229

10.2.1      MACROECONOMIC OUTLOOK  230

10.2.2      US           235

10.2.2.1  Established pharmaceutical and biotechnology sectors to

drive market          235

10.2.3      CANADA               239

10.2.3.1  Increasing funding and investments to drive market      239

10.3         EUROPE               242

10.3.1      MACROECONOMIC OUTLOOK  242

10.3.2      GERMANY           246

10.3.2.1  To dominate cell-based assays market in Europe            246

10.3.3      UK          250

10.3.3.1  Growing cancer research funding to increase demand for

cell-based assays   250

10.3.4      FRANCE                254

10.3.4.1  Growing biotechnology sector to drive market                254

10.3.5      ITALY    258

10.3.5.1  Growth of pharmaceutical industry to boost market       258

10.3.6      SPAIN    261

10.3.6.1  Rising research activity and increasing number of biotech companies to favor market growth     261

10.3.7      REST OF EUROPE             264

10.4         ASIA PACIFIC     267

10.4.1      MACROECONOMIC OUTLOOK  268

10.4.2      CHINA  273

10.4.2.1  Increasing R&D expenditure to favor market growth     273

10.4.3      JAPAN   277

10.4.3.1  Government initiatives for drug innovation to support market growth    277

10.4.4      INDIA    280

10.4.4.1  Increasing investments in R&D and funding for life science research to propel market   280

10.4.5      AUSTRALIA         284

10.4.5.1  Booming life science sector to propel market  284

10.4.6      SOUTH KOREA  287

10.4.6.1  Increasing strategic alliances to support market growth                 287

10.4.7      REST OF ASIA PACIFIC   290

10.5         LATIN AMERICA                294

10.5.1      MACROECONOMIC OUTLOOK  294

10.5.2      BRAZIL 298

10.5.2.1  Brazil to hold largest share of Latin American market   298

10.5.3      MEXICO                302

10.5.3.1  Government support for biopharmaceutical production to

support market growth        302

10.5.4      REST OF LATIN AMERICA             305

10.6         MIDDLE EAST   308

10.6.1      MACROECONOMIC OUTLOOK  308

10.6.2      GCC COUNTRIES              312

10.6.2.1  Saudi Arabia          315

10.6.2.1.1                Increasing R&D investments to drive market  315

10.6.2.2  UAE        319

10.6.2.2.1                Investments and support for biopharma sector to offer growth opportunities            319

10.6.2.3  Rest of GCC Countries        322

10.6.3      REST OF MIDDLE EAST 325

10.7         AFRICA 329

10.7.1      RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH     329

10.7.2      MACROECONOMIC OUTLOOK  329

11            COMPETITIVE LANDSCAPE         333

11.1         OVERVIEW          333

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025                 333

11.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN

CELL-BASED ASSAYS MARKET   334

11.3         REVENUE ANALYSIS, 2020–2024  336

11.4         MARKET SHARE ANALYSIS, 2024                 337

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 339

11.5.1      STARS   339

11.5.2      EMERGING LEADERS     340

11.5.3      PERVASIVE PLAYERS      340

11.5.4      PARTICIPANTS 340

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         342

11.5.5.1  Company footprint               342

11.5.5.2  Offering footprint 343

11.5.5.3  Technology footprint           344

11.5.5.4  Application Footprint           345

11.5.5.5  Region footprint   346

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        347

11.6.1      PROGRESSIVE COMPANIES         347

11.6.2      RESPONSIVE COMPANIES            347

11.6.3      DYNAMIC COMPANIES  347

11.6.4      STARTING BLOCKS         347

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 349

11.6.5.1  Detailed list of key startups/SMEs    349

11.6.5.2  Competitive benchmarking of key emerging players/startups                 351

11.7         COMPANY VALUATION & FINANCIAL METRICS 352

11.8         BRAND/PRODUCT COMPARISON             353

11.9         COMPETITIVE SCENARIO             354

11.9.1      PRODUCT/SERVICE LAUNCHES & APPROVALS  354

11.9.2      DEALS  355

11.9.3      EXPANSIONS     356

12            COMPANY PROFILES      357

12.1         INTRODUCTION              357

12.2         KEY PLAYERS     357

12.2.1      DANAHER            357

12.2.1.1  Business overview 357

12.2.1.2  Products/Services offered   359

12.2.1.3  Recent developments           361

12.2.1.3.1                Deals      361

12.2.1.3.2                Expansions             362

12.2.1.4  MnM view              362

12.2.1.4.1                Key strengths        362

12.2.1.4.2                Strategic choices   362

12.2.1.4.3                Weaknesses & competitive threats     362

12.2.2      THERMO FISHER SCIENTIFIC INC.            363

12.2.2.1  Business overview 363

12.2.2.2  Products/Services offered   364

12.2.2.3  Recent developments           368

12.2.2.3.1                Deals      368

12.2.2.3.2                Expansions             369

12.2.2.3.3                Other developments             369

12.2.2.4  MnM view              369

12.2.2.4.1                Key strengths        369

12.2.2.4.2                Strategic choices   370

12.2.2.4.3                Weaknesses & competitive threats     370

12.2.3      MERCK KGAA    371

12.2.3.1  Business overview 371

12.2.3.2  Products/Services offered   372

12.2.3.3  Recent developments           375

12.2.3.3.1                Deals      375

12.2.3.3.2                Expansions             375

12.2.3.4  MnM view              376

12.2.3.4.1                Key strengths        376

12.2.3.4.2                Strategic choices   376

12.2.3.4.3                Weaknesses & competitive threats     376

12.2.4      BD          377

12.2.4.1  Business overview 377

12.2.4.2  Products/Services offered   378

12.2.4.3  Recent developments           381

12.2.4.3.1                Product launches  381

12.2.4.3.2                Deals      381

12.2.4.4  MnM view              382

12.2.4.4.1                Key strengths        382

12.2.4.4.2                Strategic choices   382

12.2.4.4.3                Weaknesses & competitive threats     382

12.2.5      AGILENT TECHNOLOGIES, INC.                383

12.2.5.1  Business overview 383

12.2.5.2  Products/Services offered   384

12.2.5.3  Recent developments           385

12.2.5.3.1                Product launches  385

12.2.5.4  MnM view              385

12.2.5.4.1                Key strengths        385

12.2.5.4.2                Strategic choices   386

12.2.5.4.3                Weaknesses & competitive threats     386

12.2.6      LONZA 387

12.2.6.1  Business overview 387

12.2.6.2  Products/Services offered   388

12.2.6.3  Recent developments           389

12.2.6.3.1                Deals      389

12.2.6.3.2                Expansions             389

12.2.7      EUROFINS SCIENTIFIC  390

12.2.7.1  Business overview 390

12.2.7.2  Products/Services offered   391

12.2.7.3  Recent developments           393

12.2.7.3.1                Deals      393

12.2.8      CHARLES RIVER LABORATORIES               394

12.2.8.1  Business overview 394

12.2.8.2  Products/services offered   395

12.2.8.3  Recent developments           397

12.2.8.3.1                Service launches   397

12.2.8.3.2                Deals      397

12.2.9      BIO-RAD LABORATORIES, INC.  399

12.2.9.1  Business overview 399

12.2.9.2  Products/Services offered   400

12.2.10   REVVITY               402

12.2.10.1                 Business overview 402

12.2.10.2                 Products/Services offered   403

12.2.10.3                 Recent developments           405

12.2.10.3.1             Product launches  405

12.2.11   SARTORIUS AG 406

12.2.11.1                 Business overview 406

12.2.11.2                 Products/Services offered   408

12.2.11.3                 Recent developments           408

12.2.11.3.1             Expansions             408

12.2.12   CORNING INCORPORATED         409

12.2.12.1                 Business overview 409

12.2.12.2                 Products/Services offered   410

12.2.13   PROMEGA CORPORATION           412

12.2.13.1                 Business overview 412

12.2.13.2                 Products/Services offered   412

12.2.13.3                 Recent developments           413

12.2.13.3.1             Product launches  413

12.2.14   CELL SIGNALING TECHNOLOGY, INC.   414

12.2.14.1                 Business overview 414

12.2.14.2                 Products/Services offered   414

12.2.15   ENZO BIOCHEM INC.     416

12.2.15.1                 Business overview 416

12.2.15.2                 Products/Services offered   417

12.2.15.3                 Recent developments           419

12.2.15.3.1             Expansions             419

12.2.16   CARNA BIOSCIENCES, INC.          420

12.2.16.1                 Business overview 420

12.2.16.2                 Products/Services offered   421

12.2.17   INTERTEK GROUP PLC  423

12.2.17.1                 Business overview 423

12.2.17.2                 Products/services offered   424

12.2.17.3                 Recent developments           425

12.2.17.3.1             Expansions             425

12.2.18   BICO      426

12.2.18.1                 Business overview 426

12.2.18.2                 Products/Services offered   427

12.3         OTHER PLAYERS              428

12.3.1      CELL BIOLABS, INC.        428

12.3.2      REACTION BIOLOGY      429

12.3.3      AAT BIOQUEST, INC.      430

12.3.4      PESTKA BIOMEDICAL LABORATORIES, INC.        432

12.3.5      NEUROMICS       433

12.3.6      BPS BIOSCIENCE, INC.   433

12.3.7      BELLBROOK LABS           435

12.3.8      PROFACGEN      436

12.3.9      BMG LABTECH GMBH   436

12.3.10   HANUGEN THERAPEUTICS         437

12.3.11   ALTOGEN LABS                 438

12.3.12   BIOAGILYTIX LABS          439

13            APPENDIX           440

13.1         DISCUSSION GUIDE        440

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                445

13.3         CUSTOMIZATION OPTIONS        447

13.4         RELATED REPORTS         447

13.5         AUTHOR DETAILS           448

LIST OF TABLES

TABLE 1                CELL-BASED ASSAYS MARKET: INCLUSIONS AND EXCLUSIONS           39

TABLE 2                IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS              51

TABLE 3                CELL-BASED ASSAYS MARKET: IMPACT ANALYSIS            63

TABLE 4                ESTIMATED EXPENDITURE BY US NIH FOR STEM CELL RESEARCH, 2019–2025              65

TABLE 5                PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2022 VS. 2045                 66

TABLE 6                CELL-BASED ASSAYS MARKET: KEY DEVELOPMENTS              68

TABLE 7                AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021–2024            79

TABLE 8                AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024              80

TABLE 9                CELL-BASED ASSAYS MARKET: ROLE OF RAW MATERIAL VENDORS     81

TABLE 10              CELL-BASED ASSAYS MARKET: ROLE OF PRODUCT/SERVICE VENDORS  81

TABLE 11              CELL-BASED ASSAYS MARKET: ROLE OF END USERS   82

TABLE 12              CELL-BASED ASSAYS MARKET: ROLE OF REGULATORY BODIES  82

TABLE 13              NUMBER OF PATENTS APPLIED AND GRANTED, JANUARY 2014–APRIL 2025            84

TABLE 14              INNOVATIONS AND PATENT REGISTRATIONS, 2025        85

TABLE 15              CELL-BASED ASSAYS MARKET: LIST OF KEY CONFERENCES & EVENTS,

2025–2026              86

TABLE 16              AVERAGE TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS FOR

HS CODE 9027, 2024         86

TABLE 17              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  87

TABLE 18              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  87

TABLE 19              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  88

TABLE 20              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  89

TABLE 21              CELL-BASED ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS           92

TABLE 22              BUYING CRITERIA FOR CELL-BASED ASSAY PRODUCTS, BY END USER            95

TABLE 23              IMPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES),

2020–2024 (USD THOUSAND)      97

TABLE 24              IMPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (TONS)                 98

TABLE 25              EXPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES),

2020–2024 (USD THOUSAND)      99

TABLE 26              EXPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (TONS)                 100

TABLE 27              US ADJUSTED RECIPROCAL TARIFF RATES                 102

TABLE 28              CELL-BASED ASSAY PRODUCTS-RELATED TARIFF REVISION             103

TABLE 29              IMPACT ON END-USE APPLICATIONS OF CELL-BASED ASSAY PRODUCTS             105

TABLE 30              CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            108

TABLE 31              CONSUMABLES OFFERED BY KEY COMPANIES                 109

TABLE 32              CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 110

TABLE 33              CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 110

TABLE 34              NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            110

TABLE 35              EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     111

TABLE 36              ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     111

TABLE 37              LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            112

TABLE 38              MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)          112

TABLE 39              GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            112

TABLE 40              REAGENTS OFFERED BY KEY COMPANIES                 113

TABLE 41              REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 114

TABLE 42              NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     114

TABLE 43              EUROPE: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            114

TABLE 44              ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     115

TABLE 45              LATIN AMERICA: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     115

TABLE 46              MIDDLE EAST: REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)            115

TABLE 47              GCC COUNTRIES: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     116

TABLE 48              ASSAY KITS OFFERED BY KEY COMPANIES                 117

TABLE 49              ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            117

TABLE 50              ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 118

TABLE 51              NORTH AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     118

TABLE 52              EUROPE: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            118

TABLE 53              ASIA PACIFIC: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     119

TABLE 54              LATIN AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     119

TABLE 55             MIDDLE EAST: ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)            119

TABLE 56              GCC COUNTRIES: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     120

TABLE 57              REPORTER GENE ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)            121

TABLE 58              NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            121

TABLE 59              EUROPE: REPORTER GENE ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            122

TABLE 60              ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            122

TABLE 61              LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 62              MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION,

2023–2030 (USD MILLION)            123

TABLE 63              GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 64              CELL GROWTH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)            125

TABLE 65              NORTH AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            125

TABLE 66              EUROPE: CELL GROWTH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 67              ASIA PACIFIC: CELL GROWTH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 68              LATIN AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 69              MIDDLE EAST: CELL GROWTH ASSAYS MARKET, BY REGION,

2023–2030 (USD MILLION)            127

TABLE 70              GCC COUNTRIES: CELL GROWTH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 71              SECONDARY MESSENGER ASSAYS MARKET, BY REGION,

2023–2030 (USD MILLION)            129

TABLE 72              NORTH AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 129

TABLE 73              EUROPE: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            130

TABLE 74              ASIA PACIFIC: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            130

TABLE 75              LATIN AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            131

TABLE 76              MIDDLE EAST: SECONDARY MESSENGER ASSAYS MARKET, BY REGION,

2023–2030 (USD MILLION)            131

TABLE 77              GCC COUNTRIES: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 131

TABLE 78              CELL DEATH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)            132

TABLE 79              NORTH AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            133

TABLE 80              EUROPE: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     133

TABLE 81              ASIA PACIFIC: CELL DEATH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            133

TABLE 82              LATIN AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            134

TABLE 83              MIDDLE EAST: CELL DEATH ASSAYS MARKET, BY REGION,

2023–2030 (USD MILLION)            134

TABLE 84             GCC COUNTRIES: CELL DEATH ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            134

TABLE 85              OTHER ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)       135

TABLE 86              NORTH AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 87              EUROPE: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     136

TABLE 88              ASIA PACIFIC: OTHER ASSAY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            136

TABLE 89              LATIN AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            137

TABLE 90              MIDDLE EAST: OTHER ASSAY KITS MARKET, BY REGION,

2023–2030 (USD MILLION)            137

TABLE 91              GCC COUNTRIES: OTHER ASSAY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            137

TABLE 92              MICROPLATES MARKET, BY REGION, 2023–2030 (USD MILLION) 138

TABLE 93              NORTH AMERICA: MICROPLATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            139

TABLE 94             EUROPE: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            139

TABLE 95              ASIA PACIFIC: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     139

TABLE 96              LATIN AMERICA: MICROPLATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 97              MIDDLE EAST: MICROPLATES MARKET, BY REGION, 2023–2030 (USD MILLION)          140

TABLE 98              GCC COUNTRIES: MICROPLATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 99              CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            141

TABLE 100            CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION) 142

TABLE 101            NORTH AMERICA: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     142

TABLE 102            EUROPE: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            142

TABLE 103            ASIA PACIFIC: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     143

TABLE 104            LATIN AMERICA: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     143

TABLE 105          MIDDLE EAST: CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)            143

TABLE 106            GCC COUNTRIES: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     144

TABLE 107            IMMORTALIZED CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)          145

TABLE 108            NORTH AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            145

TABLE 109            EUROPE: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            145

TABLE 110            ASIA PACIFIC: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            146

TABLE 111            LATIN AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            146

TABLE 112            MIDDLE EAST: IMMORTALIZED CELL LINES MARKET, BY REGION,

2023–2030 (USD MILLION)            146

TABLE 113            GCC COUNTRIES: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 114            PRIMARY CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)            148

TABLE 115            NORTH AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 116            EUROPE: PRIMARY CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            149

TABLE 117            ASIA PACIFIC: PRIMARY CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            149

TABLE 118          LATIN AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 119            MIDDLE EAST: PRIMARY CELL LINES MARKET, BY REGION,

2023–2030 (USD MILLION)            150

TABLE 120            GCC COUNTRIES: PRIMARY CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 121            STEM CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)       152

TABLE 122            NORTH AMERICA: STEM CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 123            EUROPE: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     152

TABLE 124            ASIA PACIFIC: STEM CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 125            LATIN AMERICA: STEM CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 126            MIDDLE EAST: STEM CELL LINES MARKET, BY REGION,

2023–2030 (USD MILLION)            153

TABLE 127            GCC COUNTRIES: STEM CELL LINES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 128            PROBES & LABELS MARKET, BY REGION, 2023–2030 (USD MILLION)       155

TABLE 129            NORTH AMERICA: PROBES & LABELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            155

TABLE 130            EUROPE: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     156

TABLE 131            ASIA PACIFIC: PROBES & LABELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 132            LATIN AMERICA: PROBES & LABELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 133            MIDDLE EAST: PROBES & LABELS MARKET, BY REGION,

2023–2030 (USD MILLION)            157

TABLE 134            GCC COUNTRIES: PROBES & LABELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 135            OTHER CONSUMABLES OFFERED BY KEY COMPANIES       158

TABLE 136            OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)            158

TABLE 137            NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            159

TABLE 138            EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            159

TABLE 139            ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            159

TABLE 140            LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 141          MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION,

2023–2030 (USD MILLION)            160

TABLE 142            GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 143            INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 162

TABLE 144            NORTH AMERICA: INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            163

TABLE 145          EUROPE: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            163

TABLE 146            ASIA PACIFIC: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     163

TABLE 147            LATIN AMERICA: INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 148            MIDDLE EAST: INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)          164

TABLE 149            GCC COUNTRIES: INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 150            SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            165

TABLE 151            NORTH AMERICA: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     166

TABLE 152            EUROPE: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            166

TABLE 153            ASIA PACIFIC: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            166

TABLE 154            LATIN AMERICA: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     167

TABLE 155            MIDDLE EAST: SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            167

TABLE 156            GCC COUNTRIES: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     167

TABLE 157            SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 168

TABLE 158            NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     169

TABLE 159            EUROPE: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            169

TABLE 160            ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     169

TABLE 161            LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     170

TABLE 162          MIDDLE EAST: SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)            170

TABLE 163            GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     170

TABLE 164            CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            172

TABLE 165            CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION,

2023–2030 (USD MILLION)            173

TABLE 166            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY,

BY COUNTRY, 2023–2030 (USD MILLION)               173

TABLE 167            EUROPE: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)                 174

TABLE 168            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)            174

TABLE 169            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY,

BY COUNTRY, 2023–2030 (USD MILLION)               175

TABLE 170            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2023–2030 (USD MILLION)                 175

TABLE 171            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY,

BY COUNTRY, 2023–2030 (USD MILLION)               175

TABLE 172            CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023–2030 (USD MILLION)            176

TABLE 173            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)            177

TABLE 174            EUROPE: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING,

BY COUNTRY, 2023–2030 (USD MILLION)               177

TABLE 175            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 178

TABLE 176            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 178

TABLE 177            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023–2030 (USD MILLION) 178

TABLE 178            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 179

TABLE 179            CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY REGION,

2023–2030 (USD MILLION)            180

TABLE 180            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,

BY COUNTRY, 2023–2030 (USD MILLION)               180

TABLE 181            EUROPE: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,

BY COUNTRY, 2023–2030 (USD MILLION)               181

TABLE 182            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,

BY COUNTRY, 2023–2030 (USD MILLION)               181

TABLE 183            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,

BY COUNTRY, 2023–2030 (USD MILLION)               182

TABLE 184            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,

BY REGION, 2023–2030 (USD MILLION)   182

TABLE 185            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,

BY COUNTRY, 2023–2030 (USD MILLION)               182

TABLE 186            OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION,

2023–2030 (USD MILLION)            183

TABLE 187            NORTH AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               183

TABLE 188            EUROPE: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            184

TABLE 189            ASIA PACIFIC: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            184

TABLE 190            LATIN AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 191            MIDDLE EAST: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)            185

TABLE 192            GCC COUNTRIES: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 193          CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            187

TABLE 194            CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 188

TABLE 195            CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)            188

TABLE 196            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            189

TABLE 197            EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               189

TABLE 198            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190

TABLE 199            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190

TABLE 200            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 191

TABLE 201            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 191

TABLE 202            CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION,

2023–2030 (USD MILLION)            192

TABLE 203            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               193

TABLE 204            EUROPE: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)                 193

TABLE 205            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)            194

TABLE 206            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 207            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION, 2023–2030 (USD MILLION)                 195

TABLE 208            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 209            CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY REGION, 2023–2030 (USD MILLION)            196

TABLE 210            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)            197

TABLE 211            EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               197

TABLE 212            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 213            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 198

TABLE 214            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES,

BY REGION, 2023–2030 (USD MILLION)   198

TABLE 215            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 199

TABLE 216            CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023–2030 (USD MILLION)            200

TABLE 217            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)            200

TABLE 218            EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               201

TABLE 219            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 201

TABLE 220            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 202

TABLE 221            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023–2030 (USD MILLION) 202

TABLE 222            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 202

TABLE 223            CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION,

2023–2030 (USD MILLION)            204

TABLE 224            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH,

BY COUNTRY, 2023–2030 (USD MILLION)               204

TABLE 225            EUROPE: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)                 205

TABLE 226            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)                 205

TABLE 227            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH,

BY COUNTRY, 2023–2030 (USD MILLION)               206

TABLE 228            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2023–2030 (USD MILLION)                 206

TABLE 229            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH,

BY COUNTRY, 2023–2030 (USD MILLION)               206

TABLE 230            CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION,

2023–2030 (USD MILLION)            207

TABLE 231            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               207

TABLE 232            EUROPE: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)                 208

TABLE 233            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)            208

TABLE 234            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 235            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION, 2023–2030 (USD MILLION)                 209

TABLE 236            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 237            CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION,

2023–2030 (USD MILLION)            210

TABLE 238            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               211

TABLE 239            EUROPE: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            211

TABLE 240            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               212

TABLE 241            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               212

TABLE 242            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   213

TABLE 243            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               213

TABLE 244            CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)            215

TABLE 245            PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)                216

TABLE 246            CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          217

TABLE 247            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   217

TABLE 248            EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     218

TABLE 249            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     218

TABLE 250            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     219

TABLE 251            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          219

TABLE 252            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     219

TABLE 253            CELL-BASED ASSAYS MARKET FOR CROS, BY REGION, 2023–2030 (USD MILLION)          221

TABLE 254            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,

2023–2030 (USD MILLION)            221

TABLE 255            EUROPE: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,

2023–2030 (USD MILLION)            222

TABLE 256            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,

2023–2030 (USD MILLION)            222

TABLE 257            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,

2023–2030 (USD MILLION)            223

TABLE 258            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR CROS, BY REGION,

2023–2030 (USD MILLION)            223

TABLE 259            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,

2023–2030 (USD MILLION)            223

TABLE 260            CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY REGION, 2023–2030 (USD MILLION)   224

TABLE 261            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     225

TABLE 262            EUROPE: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 225

TABLE 263            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       226

TABLE 264            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       226

TABLE 265            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)       226

TABLE 266            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       227

TABLE 267            CELL-BASED ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)            229

TABLE 268            NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            231

TABLE 269            NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            232

TABLE 270            NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                232

TABLE 271            NORTH AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)                233

TABLE 272            NORTH AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)                233

TABLE 273            NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            233

TABLE 274            NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            234

TABLE 275            NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       234

TABLE 276            NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            234

TABLE 277          US: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            236

TABLE 278            US: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       236

TABLE 279            US: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 237

TABLE 280            US: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237

TABLE 281            US: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            237

TABLE 282            US: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              238

TABLE 283            US: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 238

TABLE 284          US: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)            238

TABLE 285            CANADA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            239

TABLE 286            CANADA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            240

TABLE 287            CANADA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       240

TABLE 288            CANADA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       240

TABLE 289            CANADA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            241

TABLE 290            CANADA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            241

TABLE 291            CANADA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         241

TABLE 292            CANADA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            242

TABLE 293            EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     243

TABLE 294            EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            243

TABLE 295            EUROPE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            244

TABLE 296            EUROPE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       244

TABLE 297            EUROPE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       244

TABLE 298            EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            245

TABLE 299            EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            245

TABLE 300            EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         245

TABLE 301            EUROPE: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            246

TABLE 302            GERMANY: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            247

TABLE 303            GERMANY: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            247

TABLE 304            GERMANY: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       248

TABLE 305            GERMANY: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       248

TABLE 306            GERMANY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            248

TABLE 307            GERMANY: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            249

TABLE 308            GERMANY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            249

TABLE 309            GERMANY: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            249

TABLE 310            UK: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     251

TABLE 311            UK: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       251

TABLE 312            UK: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252

TABLE 313            UK: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 252

TABLE 314            UK: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            252

TABLE 315            UK: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              253

TABLE 316            UK: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 253

TABLE 317          UK: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)            253

TABLE 318            FRANCE: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            255

TABLE 319            FRANCE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            255

TABLE 320            FRANCE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       256

TABLE 321            FRANCE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       256

TABLE 322            FRANCE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            256

TABLE 323            FRANCE: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            257

TABLE 324            FRANCE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         257

TABLE 325            FRANCE: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            257

TABLE 326            ITALY: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     258

TABLE 327            ITALY: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       258

TABLE 328            ITALY: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 259

TABLE 329            ITALY: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 259

TABLE 330            ITALY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            259

TABLE 331            ITALY: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            260

TABLE 332            ITALY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         260

TABLE 333            ITALY: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                260

TABLE 334            SPAIN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     261

TABLE 335            SPAIN: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       262

TABLE 336            SPAIN: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 262

TABLE 337            SPAIN: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262

TABLE 338            SPAIN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            263

TABLE 339            SPAIN: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            263

TABLE 340            SPAIN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         263

TABLE 341            SPAIN: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                264

TABLE 342          REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            264

TABLE 343            REST OF EUROPE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                265

TABLE 344            REST OF EUROPE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)                265

TABLE 345            REST OF EUROPE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)                266

TABLE 346          REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            266

TABLE 347          REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            266

TABLE 348            REST OF EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 267

TABLE 349          REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            267

TABLE 350            ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            270

TABLE 351            ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            270

TABLE 352            ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                271

TABLE 353            ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            271

TABLE 354            ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            271

TABLE 355            ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            272

TABLE 356            ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            272

TABLE 357            ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273

TABLE 358            ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            273

TABLE 359            CHINA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     274

TABLE 360            CHINA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            274

TABLE 361            CHINA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       275

TABLE 362            CHINA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       275

TABLE 363            CHINA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            275

TABLE 364            CHINA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            276

TABLE 365            CHINA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         276

TABLE 366            CHINA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                276

TABLE 367            JAPAN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     277

TABLE 368            JAPAN: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       278

TABLE 369            JAPAN: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 278

TABLE 370            JAPAN: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 279

TABLE 371            JAPAN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            279

TABLE 372            JAPAN: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            279

TABLE 373            JAPAN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         280

TABLE 374            JAPAN: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                280

TABLE 375            INDIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     281

TABLE 376            INDIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       281

TABLE 377            INDIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 282

TABLE 378            INDIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282

TABLE 379            INDIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            282

TABLE 380            INDIA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            283

TABLE 381            INDIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         283

TABLE 382            INDIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                283

TABLE 383            AUSTRALIA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            284

TABLE 384            AUSTRALIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            285

TABLE 385            AUSTRALIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            285

TABLE 386            AUSTRALIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            285

TABLE 387            AUSTRALIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            286

TABLE 388            AUSTRALIA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            286

TABLE 389            AUSTRALIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            286

TABLE 390            AUSTRALIA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            287

TABLE 391            SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            287

TABLE 392            SOUTH KOREA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                288

TABLE 393            SOUTH KOREA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            288

TABLE 394            SOUTH KOREA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            288

TABLE 395            SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            289

TABLE 396            SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            289

TABLE 397            SOUTH KOREA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289

TABLE 398            SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            290

TABLE 399            REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            291

TABLE 400          REST OF ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 401            REST OF ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)                292

TABLE 402            REST OF ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)                292

TABLE 403            REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            292

TABLE 404            REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            293

TABLE 405            REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       293

TABLE 406            REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            293

TABLE 407            LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            295

TABLE 408            LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            295

TABLE 409            LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                296

TABLE 410            LATIN AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            296

TABLE 411            LATIN AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            297

TABLE 412            LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            297

TABLE 413            LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            297

TABLE 414            LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 298

TABLE 415            LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            298

TABLE 416            BRAZIL: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     299

TABLE 417            BRAZIL: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            299

TABLE 418            BRAZIL: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       300

TABLE 419            BRAZIL: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       300

TABLE 420            BRAZIL: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            300

TABLE 421            BRAZIL: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            301

TABLE 422            BRAZIL: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         301

TABLE 423            BRAZIL: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                301

TABLE 424            MEXICO: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     302

TABLE 425            MEXICO: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            302

TABLE 426            MEXICO: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       303

TABLE 427            MEXICO: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       303

TABLE 428            MEXICO: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            303

TABLE 429            MEXICO: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            304

TABLE 430            MEXICO: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         304

TABLE 431            MEXICO: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            304

TABLE 432            REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            305

TABLE 433            REST OF LATIN AMERICA: CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            305

TABLE 434            REST OF LATIN AMERICA: ASSAY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            306

TABLE 435            REST OF LATIN AMERICA: CELL LINES MARKET, BY TYPE,

2023–2030 (USD MILLION)            306

TABLE 436            REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            306

TABLE 437            REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            307

TABLE 438            REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       307

TABLE 439            REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            307

TABLE 440            MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION,

2023–2030 (USD MILLION)            308

TABLE 441            MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            309

TABLE 442            MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                309

TABLE 443            MIDDLE EAST: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            310

TABLE 444            MIDDLE EAST: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            310

TABLE 445            MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            310

TABLE 446            MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            311

TABLE 447            MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 311

TABLE 448            MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            311

TABLE 449          GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            312

TABLE 450          GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            312

TABLE 451            GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                313

TABLE 452          GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            313

TABLE 453          GCC COUNTRIES: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            314

TABLE 454          GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            314

TABLE 455          GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            314

TABLE 456            GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 315

TABLE 457          GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            315

TABLE 458            SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            316

TABLE 459            SAUDI ARABIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                316

TABLE 460            SAUDI ARABIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)            317

TABLE 461            SAUDI ARABIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)            317

TABLE 462            SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            317

TABLE 463            SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            318

TABLE 464            SAUDI ARABIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 318

TABLE 465            SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            318

TABLE 466            UAE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     319

TABLE 467            UAE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)       319

TABLE 468            UAE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 320

TABLE 469            UAE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 320

TABLE 470            UAE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            320

TABLE 471            UAE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              321

TABLE 472            UAE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         321

TABLE 473            UAE: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                321

TABLE 474            REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            322

TABLE 475            REST OF GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            323

TABLE 476            REST OF GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            323

TABLE 477          REST OF GCC COUNTRIES: CELL LINES MARKET, BY TYPE,

2023–2030 (USD MILLION)            324

TABLE 478            REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 324

TABLE 479            REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            324

TABLE 480            REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       325

TABLE 481            REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            325

TABLE 482            REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            326

TABLE 483            REST OF MIDDLE EAST: CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            326

TABLE 484            REST OF MIDDLE EAST: ASSAY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 485            REST OF MIDDLE EAST: CELL LINES MARKET, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 486            REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            327

TABLE 487            REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            328

TABLE 488            REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       328

TABLE 489            REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER,

2023–2030 (USD MILLION)            328

TABLE 490            AFRICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     330

TABLE 491            AFRICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)            330

TABLE 492            AFRICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)       331

TABLE 493            AFRICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)       331

TABLE 494            AFRICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            331

TABLE 495            AFRICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            332

TABLE 496            AFRICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         332

TABLE 497            AFRICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)                332

TABLE 498            OVERVIEW OF STRATEGIES DEPLOYED BY MANUFACTURING COMPANIES,

JANUARY 2021–APRIL 2025            334

TABLE 499            CELL-BASED ASSAYS MARKET: DEGREE OF COMPETITION 338

TABLE 500            CELL-BASED ASSAYS MARKET: OFFERING FOOTPRINT       343

TABLE 501            CELL-BASED ASSAYS MARKET: TECHNOLOGY FOOTPRINT       344

TABLE 502            CELL-BASED ASSAYS MARKET: APPLICATION FOOTPRINT       345

TABLE 503            CELL-BASED ASSAYS MARKET: REGION FOOTPRINT       346

TABLE 504            CELL-BASED ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES              349

TABLE 505            CELL-BASED ASSAYS MARKET: COMPETITIVE BENCHMARKING OF

KEY EMERGING PLAYERS/STARTUPS     351

TABLE 506            CELL-BASED ASSAYS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025           354

TABLE 507            CELL-BASED ASSAYS MARKET: DEALS, JANUARY 2021–APRIL 2025                355

TABLE 508            CELL-BASED ASSAYS MARKET: EXPANSIONS, JANUARY 2021–APRIL 2025            356

TABLE 509            DANAHER: COMPANY OVERVIEW            357

TABLE 510            DANAHER: PRODUCTS/SERVICES OFFERED                 359

TABLE 511            DANAHER: DEALS, JANUARY 2021–APRIL 2025                 361

TABLE 512            DANAHER: EXPANSIONS, JANUARY 2021–APRIL 2025        362

TABLE 513            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          363

TABLE 514            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED               364

TABLE 515            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–APRIL 2025            368

TABLE 516          THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–APRIL 2025            369

TABLE 517            THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS,

JANUARY 2021–APRIL 2025            369

TABLE 518            MERCK KGAA: COMPANY OVERVIEW     371

TABLE 519            MERCK KGAA: PRODUCTS/SERVICES OFFERED                 372

TABLE 520            MERCK KGAA: DEALS, JANUARY 2021–APRIL 2025                 375

TABLE 521            MERCK KGAA: EXPANSIONS, JANUARY 2021–APRIL 2025           375

TABLE 522            BD: BUSINESS OVERVIEW             377

TABLE 523            BD: PRODUCTS/SERVICES OFFERED      378

TABLE 524            BD: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025           381

TABLE 525            BD: DEALS, JANUARY 2021–APRIL 2025    381

TABLE 526            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          383

TABLE 527            AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED               384

TABLE 528            AGILENT TECHNOLOGIES, INC.: PRODUCTS LAUNCHES,

JANUARY 2021–APRIL 2025            385

TABLE 529            LONZA: COMPANY OVERVIEW  387

TABLE 530            LONZA: PRODUCTS/SERVICES OFFERED                 388

TABLE 531            LONZA: DEALS, JANUARY 2021–APRIL 2025                 389

TABLE 532            LONZA: EXPANSIONS, JANUARY 2021–APRIL 2025                 389

TABLE 533            EUROFINS SCIENTIFIC: COMPANY OVERVIEW                 390

TABLE 534            EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED             391

TABLE 535            EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–APRIL 2025           393

TABLE 536            CHARLES RIVER LABORATORIES: COMPANY OVERVIEW          394

TABLE 537            CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED               395

TABLE 538            CHARLES RIVER LABORATORIES: SERVICE LAUNCHES,

JANUARY 2021–APRIL 2025            397

TABLE 539            CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–APRIL 2025            397

TABLE 540            BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW          399

TABLE 541            BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED               400

TABLE 542            REVVITY: COMPANY OVERVIEW               402

TABLE 543            REVVITY: PRODUCTS/SERVICES OFFERED                 403

TABLE 544            REVVITY: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025           405

TABLE 545            SARTORIUS AG: COMPANY OVERVIEW  406

TABLE 546            SARTORIUS AG: PRODUCTS/SERVICES OFFERED             408

TABLE 547            SARTORIUS AG: EXPANSIONS, JANUARY 2021–APRIL 2025           408

TABLE 548            CORNING INCORPORATED: COMPANY OVERVIEW          409

TABLE 549            CORNING INCORPORATED: PRODUCTS/SERVICES OFFERED               410

TABLE 550            PROMEGA CORPORATION: COMPANY OVERVIEW          412

TABLE 551            PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED               412

TABLE 552            PROMEGA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025   413

TABLE 553            CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW   414

TABLE 554            CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SERVICES OFFERED               414

TABLE 555            ENZO BIOCHEM INC.: COMPANY OVERVIEW                 416

TABLE 556            ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED             417

TABLE 557            ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021–APRIL 2025                419

TABLE 558            CARNA BIOSCIENCES, INC.: BUSINESS OVERVIEW          420

TABLE 559            CARNA BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED               421

TABLE 560            INTERTEK GROUP PLC: COMPANY OVERVIEW                 423

TABLE 561            INTERTEK GROUP PLC: PRODUCTS /SERVICES OFFERED             424

TABLE 562            INTERTEK GROUP PLC: EXPANSIONS, JANUARY 2021–APRIL 2025                425

TABLE 563            BICO: COMPANY OVERVIEW      426

TABLE 564            BICO: PRODUCTS/SERVICES OFFERED  427

LIST OF FIGURES

FIGURE 1              CELL-BASED ASSAYS MARKET: SEGMENTS & REGIONS CONSIDERED 40

FIGURE 2              RESEARCH DESIGN         43

FIGURE 3              BREAKDOWN OF PRIMARIES: CELL-BASED ASSAYS MARKET               45

FIGURE 4              CELL-BASED ASSAYS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024      46

FIGURE 5              MARKET SIZE ESTIMATION: GLOBAL MARKET ESTIMATION

(BOTTOM-UP APPROACH), 2024                47

FIGURE 6              ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION:

REVENUE SHARE ANALYSIS (2024)            47

FIGURE 7              MARKET SIZE VALIDATION FROM PRIMARY SOURCES             48

FIGURE 8              MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH                49

FIGURE 9              CELL-BASED ASSAYS MARKET: CAGR PROJECTIONS   50

FIGURE 10            DATA TRIANGULATION METHODOLOGY                 52

FIGURE 11            CELL-BASED ASSAYS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)      55

FIGURE 12            CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)      56

FIGURE 13           CELL-BASED ASSAYS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)      56

FIGURE 14            CELL-BASED ASSAYS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      57

FIGURE 15            GEOGRAPHICAL SNAPSHOT OF CELL-BASED ASSAYS MARKET               58

FIGURE 16            GROWING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET        59

FIGURE 17            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024       60

FIGURE 18            CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024             60

FIGURE 19            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT HELD

MAJOR MARKET SHARE IN 2024 61

FIGURE 20            ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH

DURING FORECAST PERIOD       61

FIGURE 21            CELL-BASED ASSAYS MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES     62

FIGURE 22            AGE-STANDARDIZED RATE (WORLD) PER 100,000 CANCER

INCIDENCES IN BOTH SEXES, 2022            67

FIGURE 23            CELL-BASED ASSAYS MARKET: VALUE CHAIN ANALYSIS            77

FIGURE 24            PRICING ANALYSIS FOR CELL-BASED ASSAY PRODUCTS, 2022–2024    78

FIGURE 25            CELL-BASED ASSAYS MARKET ECOSYSTEM                 80

FIGURE 26            TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS   83

FIGURE 27            PATENT APPLICATION IN CELL-BASED ASSAYS MARKET,

JANUARY 2014–APRIL 2025            84

FIGURE 28            CELL-BASED ASSAYS MARKET: PORTER’S FIVE ANALYSIS            92

FIGURE 29            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF

CELL-BASED ASSAY PRODUCTS                 94

FIGURE 30            KEY BUYING CRITERIA FOR END USERS                 95

FIGURE 31            CELL-BASED ASSAYS MARKET: INVESTMENT AND

FUNDING SCENARIO, 2020-2024 96

FIGURE 32            IMPACT OF AI/GEN AI ON CELL-BASED ASSAYS MARKET               101

FIGURE 33            INSTRUMENTS MARKET (FLOW CYTOMETERS) FOR CELL-BASED ASSAYS,

2023–2030 (THOUSAND UNITS)  162

FIGURE 34            WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2021–2028              216

FIGURE 35            NORTH AMERICA: CELL-BASED ASSAYS MARKET SNAPSHOT       231

FIGURE 36            ASIA PACIFIC: CELL-BASED ASSAYS MARKET SNAPSHOT          269

FIGURE 37            REVENUE ANALYSIS OF KEY PLAYERS IN CELL-BASED ASSAYS

MARKET (2020–2024)       337

FIGURE 38            MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL-BASED

ASSAYS MARKET (2024) 338

FIGURE 39            CELL-BASED ASSAYS MARKET: COMPANY EVALUATION

MATRIX (KEY PLAYERS), 2024     341

FIGURE 40            CELL-BASED ASSAYS MARKET: COMPANY FOOTPRINT       342

FIGURE 41            CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX, (STARTUPS/SMES), 2024                 348

FIGURE 42            EV/EBITDA OF KEY VENDORS   352

FIGURE 43            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                352

FIGURE 44            CELL-BASED ASSAYS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     353

FIGURE 45            DANAHER: COMPANY SNAPSHOT (2024)                 358

FIGURE 46            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             364

FIGURE 47            MERCK KGAA: COMPANY SNAPSHOT (2024)                 372

FIGURE 48            BD: COMPANY SNAPSHOT (2024)              378

FIGURE 49            AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)             384

FIGURE 50            LONZA: COMPANY SNAPSHOT (2024)     388

FIGURE 51            EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)    391

FIGURE 52            CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)             395

FIGURE 53            BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)             400

FIGURE 54            REVVITY: COMPANY SNAPSHOT (2024)  403

FIGURE 55            SARTORIUS AG: COMPANY SNAPSHOT (2024)                 407

FIGURE 56            CORNING INCORPORATED: COMPANY SNAPSHOT (2024)             410

FIGURE 57            ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2024)    416

FIGURE 58            CARNA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)             421

FIGURE 59            INTERTEK GROUP PLC: COMPANY SNAPSHOT (2024)    424

FIGURE 60            BICO: COMPANY SNAPSHOT (2024)          427

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• UV安定剤市場 – 2030年までの世界予測 2025-05-16
• 産業用通信市場 – 2030年までの世界予測 2025-05-16
• 経腸栄養装置市場 – 2030年までの世界予測 2025-05-15
• データセンターGPU市場 – 2030年までの世界予測 2025-05-15
• ステンレス鋼シームレスパイプ市場 – 2030年までの世界予測 2025-05-15

MarketsandMarkets  出版レポート一覧